- Report
- January 2022
- 121 Pages
Global
From €4593EUR$4,750USD£3,919GBP
- Report
- August 2020
- 114 Pages
North America
From €3626EUR$3,750USD£3,094GBP
- Report
- April 2020
- 113 Pages
Global
From €4593EUR$4,750USD£3,919GBP
- Report
- April 2018
- 112 Pages
Global
From €4109EUR$4,250USD£3,506GBP
- Report
- March 2018
- 118 Pages
Global
From €4109EUR$4,250USD£3,506GBP
- Report
- April 2023
- 137 Pages
Global
From €7252EUR$7,500USD£6,187GBP
- Report
- September 2022
- 235 Pages
Global
From €7252EUR$7,500USD£6,187GBP
- Report
- September 2022
- 117 Pages
Global
From €3819EUR$3,950USD£3,259GBP
- Report
- September 2021
- 102 Pages
Global
From €4351EUR$4,500USD£3,712GBP
From €2514EUR$2,600USD£2,145GBP
- Report
- October 2018
- 18 Pages
Global
From €9669EUR$10,000USD£8,250GBP
- Report
- October 2018
- 17 Pages
Global
From €9669EUR$10,000USD£8,250GBP
- Report
- March 2023
- 157 Pages
Global
From €2417EUR$2,500USD£2,062GBP
- Report
- February 2024
- 95 Pages
Global
From €3500EUR$3,878USD£3,091GBP
- Report
- November 2023
- 103 Pages
Global
From €3500EUR$3,878USD£3,091GBP
- Report
- September 2023
- 115 Pages
Global
From €3500EUR$3,878USD£3,091GBP
- Report
- August 2023
- 77 Pages
Global
From €3500EUR$3,878USD£3,091GBP
- Report
- October 2022
- 94 Pages
Global
From €1934EUR$2,000USD£1,650GBP
- Report
- November 2021
- 747 Pages
Global
From €3868EUR$4,000USD£3,300GBP
- Report
- May 2023
- 140 Pages
Global
From €5800EUR$5,999USD£4,949GBP
Doxorubicin is an oncology drug used to treat a variety of cancers, including leukemia, lymphoma, and breast, ovarian, and bladder cancer. It is a type of anthracycline antibiotic, derived from Streptomyces peucetius, and works by interfering with the growth of cancer cells. It is administered intravenously, and is often used in combination with other drugs.
Doxorubicin is one of the most widely used chemotherapy drugs, and is often used in combination with other drugs to treat a variety of cancers. It is also used to treat Kaposi's sarcoma, a type of skin cancer. Side effects of doxorubicin include nausea, vomiting, hair loss, and an increased risk of infection.
The doxorubicin market is highly competitive, with many companies offering generic versions of the drug. Some of the major players in the market include Pfizer, Novartis, Merck, Bristol-Myers Squibb, and AstraZeneca. Show Less Read more